5-amino-1MQ myths: what the research does not show
5-amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, and its published research to date is laboratory research: cell studies, mouse studies and a rat pharmacokinetic study, with no human trials. This page lays out what that mouse and cell work found and which of the popular claims go further than it does.
Findings
- In diet-induced obese mice, a methylquinolinium NNMT inhibitor reduced body weight and white fat mass without lowering food intake (Biochem Pharmacol, 2018).
- In 24-month-old mice with a muscle injury, an NNMT inhibitor raised peak muscle torque by about 70% against controls (Biochem Pharmacol, 2019).
- Aged sedentary mice given an NNMT inhibitor had about 40% greater grip strength than sedentary controls (Sci Rep, 2024).
- The biggest gap: we found no published human study of 5-amino-1MQ, for any outcome, including safety.
View product →Myth: 5-amino-1MQ is proven to burn fat in people
False on the current record. The fat-loss evidence comes from mice fed a high-fat diet. In the 2018 study, an NNMT inhibitor from this compound family reduced body weight, white fat mass and fat cell size and lowered cholesterol, while food intake did not change. These are real, controlled animal results. We found no human trial, so the size of any effect in people is unknown.
Myth: it melts fat without any change in diet
Partly true, in mice. The 2018 mice kept eating a high-fat diet and still lost weight, which is the source of this claim. But the strongest mouse result came from combining the inhibitor with a switch to a lean diet: in 2021, that combination brought body composition and liver fat back to the levels of lean control mice, better than the diet change alone. Even in mice, diet still mattered.
Myth: 5-amino-1MQ is exercise in a pill
The phrase borrows from a 2024 mouse paper title, and it overstates the finding. Aged sedentary mice given an NNMT inhibitor had about 40% greater grip strength than sedentary controls, while exercise alone gave about 20%. The two together gave about 60%, so the effects added up rather than one replacing the other. The authors studied mice aged 22 to 24 months; no human muscle data exist.
Myth: it rebuilds aged muscle
Partly true, in old injured mice. In the 2019 study, aged mice with an induced muscle injury that received an NNMT inhibitor showed more muscle stem cell activity, nearly twice the muscle fibre cross-sectional area and about 70% higher peak torque than controls. That is a striking animal result. It was measured after a chemical injury in one muscle of mice, not in ageing people.
Myth: 5-amino-1MQ raises your NAD+
Partly true, in cells. NNMT uses up nicotinamide, a building block of NAD+. In cultured fat cells, NNMT inhibitors lowered NNMT’s product and raised intracellular NAD+ (2018). A 2014 mouse study that switched off the NNMT gene in fat and liver also found higher NAD+ in fat tissue. NAD+ has not been measured in people given 5-amino-1MQ.
Myth: 5-amino-1MQ is a peptide
Not chemically. It is a small quinolinium molecule, not a chain of amino acids. It is often sold alongside research peptides, which is where the label comes from. The difference shows in how it is studied: a 2021 rat study measured how much of the compound reached the blood by two routes, and reported substantial exposure from both.
What 5-amino-1MQ cannot promise
The mouse work is consistent and comes mainly from one research program. It has not crossed into people yet.
- It cannot promise fat loss in people; there is no human trial.
- It cannot promise stronger muscles in older adults; the data are from aged mice.
- It cannot promise a known human safety profile; mice showed no observable adverse effects, and people have not been studied.
- It cannot promise that every NNMT inhibitor result applies to 5-amino-1MQ; some abstracts do not name the exact compound tested.
Where the evidence stands
5-amino-1MQ is not an approved medicine in Canada for any use. Its published record is cell, mouse and rat research from a small number of groups. No human trial results have been published. Research suppliers offer it for laboratory work only.
Vistara Labs supplies 5-amino-1MQ as a laboratory research material. The page above is about the published research, not a claim about our product.
Frequently asked questions
Has 5-amino-1MQ been tested in humans?
We found no published human study. The research consists of cell studies, mouse studies of obesity and ageing muscle, and a rat study of how the compound is absorbed.
What did the 5-amino-1MQ mouse studies show?
In obese mice, an NNMT inhibitor from this family lowered body weight and fat mass without changing food intake. In aged mice, NNMT inhibition improved grip strength and muscle recovery after injury.
Is 5-amino-1MQ a peptide?
No. It is a small quinolinium molecule that blocks the enzyme NNMT. It is often grouped with research peptides but is not built from amino acids.
Sources: Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PMID 29155147. Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019. PMID 30753815. Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024. PMID 38969654. Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep. 2021. PMID 33707534. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID 24717514. Awosemo O, Neelakantan H, Watowich S, et al. Development and validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021. PMID 34304009.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
5-Amino-1MQ is a small-molecule NNMT inhibitor rather than a peptide. No completed human clinical trial was identified; the research below is preclinical.
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in miceCharacterises 5-Amino-1MQ as a selective, cell-permeable NNMT inhibitor in laboratory studies. No human trial identified.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.
